Sutro Biopharma, Inc. · NASDAQ:STRO
Sutro Biopharma — Conference Presentation (March 2025)
9 slides from Sutro Biopharma's conference presentation, March 2025
Slide 1: Sutro Biopharma
Sutro Biopharma March 2025 NASDAQ: STRO 1 NON CONFIDENTIAL
Slide 2: Forward-Looking Statements
2 Forward-Looking Statements This presentation and the accompanying oral presentation contain “forward-looking” statements that are based on our management’s beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other than sta
Slide 3: Strategic Restructuring to Accelerate Development of Next-Generation ADC Pipeline and Significantly Extend Cash Runway
Strategic Restructuring to Accelerate Development of Next-Generation ADC Pipeline and Significantly Extend Cash Runway Pipeline Restructuring and Optimized Clinical Priorities • Resources will be concentrated on advancing highly promising, novel ADCs for indications where there is greatest need • Th
Slide 4: Sutro Team Comprised of Industry Leaders
Sutro Team Comprised of Industry Leaders Jane Chung, RPh Hans-Peter Gerber, PhD Barbara Leyman, PhD Chief Executive Officer Chief Scientific Officer Chief Business Development Officer Ed Albini, MBA David Pauling, JD, MA Venkatesh Srinivasan, PhD Chief Financial Officer General Counsel Chief Technic
Slide 5: Proprietary XpressCF Technology Platform: Enabling Precise Design of ADCs
Proprietary XpressCF® Technology Platform: Enabling Precise Design of ADCs with a Wide Range of Features Not Possible with Other Platforms With Our Next-Generation ADCs We Strive to Mitigate Toxicity Risk and Increase Dose to Improve Efficacy and Broaden the Addressable Patient Population Key Differ
Slide 6: Pipeline of Next-Generation ADCs
Pipeline of Next-Generation ADCs WORLDWIDE OR PHASE 3/ GEOGRAPHIC PROGRAM MODALITY/TARGET INDICATION DISCOVERY PRECLINICAL PHASE 1/1B PHASE 2 REGISTRATIONAL PARTNER WHOLLY-OWNED PROGRAMS STRO-004 Tissue Factor ADC Solid Tumors STRO-006 Integrin αvβ6 Solid Tumors STRO-00X Dual Payload ADC Solid Tumor
Slide 7: Novel ADCs Designed for Improved Clinical Benefit to Address Significant Unmet Need
Novel ADCs Designed for Improved Clinical Benefit to Address Significant Unmet Need Three INDs Planned Over 3 Years STRO-004 STRO-006 Dual Payload Programs Exatecan ADC Targeting Tissue Factor Integrin-Beta 6 ADC • Optimally designed for improved • Successfully identified specific and • Potential to
Slide 8: Our Clinical and Corporate Priorities
Our Clinical and Corporate Priorities Sutro's Wholly-Owned Programs STRO-004 2H 2025: IND filing and first-in-human studies planned Exatecan ADC Targeting Tissue Factor 2026: Phase 1a/b dose escalation data expected 2027: Phase 1a/b dose expansion data expected (initial response data anticipated 1H
Slide 9: Q&A
Q&A 9 NON CONFIDENTIAL
Sutro Biopharma — Conference Presentation (March 2025) on 6ix